This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Poseida Therapeutics 경영진
경영진 기준 점검 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
핵심 정보
Kristin Yarema
최고경영자
US$2.6m
총 보수
| CEO 급여 비율 | 14.75% |
| CEO 재임 기간 | 1yr |
| CEO 지분 보유율 | n/a |
| 경영진 평균 재임 기간 | 3yrs |
| 이사회 평균 재임 기간 | 3.7yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • Nov 26
Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities
Summary Roche is acquiring Poseida Therapeutics for $1.5 billion, with the current market cap reflecting approximately 60% of the deal. More importantly, this deal shows that cell therapies are in play for M&A activity. Furthermore, it gives us an important benchmark for helping to evaluate the “fair” value of biotechs developing promising immunotherapies. Read the full article on Seeking Alpha분석 기사 • Oct 19
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%
Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) shares have had a horrible month, losing 30% after a relatively good period...Seeking Alpha • Sep 30
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Summary Positive interim results released from phase 1/1b study using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory Multiple Myeloma. The global multiple myeloma market is projected to reach $44.22 billion by 2032. Interim data update for use of P-CD19CD20-ALLO1 in ongoing phase 1 study targeting patients with B-cell malignancies expected in the 2nd half of 2024 pending coordination with Roche. Poseida has already been able to establish collaboration agreements with Roche and Astellas to advance its allogeneic CAR-Ts for oncology use. Read the full article on Seeking AlphaSeeking Alpha • Sep 09
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Summary Poseida Therapeutics shows promising early results in myeloma with their BCMA-directed allogeneic CAR T-cell therapy, achieving a 60% response rate in phase 1 trials. Financially stable with $30.5 million in cash, $207.3 million in short-term investments, and a $20 million milestone payment from Roche extending their cash runway. Strong partnerships with big pharma and deep cash reserves provide a solid foundation for continued development and potential non-dilutive funding. Despite uncertainties in phase 1 trials, PSTX's low market valuation and encouraging data make it a worthwhile speculative investment with limited downside risk. Read the full article on Seeking Alpha분석 기사 • Aug 28
Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) shares have had a horrible month, losing 29% after a relatively good period...분석 기사 • May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Apr 09
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) shares have had a horrible month, losing 27% after a relatively good period...Seeking Alpha • Mar 17
Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Summary Additional results from the phase 1 study, using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma, are expected at AACR on April 8th of 2024; Other data 2nd half of 2024. The global multiple myeloma market size is projected to reach $31 billion by 2026. Allogenic off-the-shelf CAR-T technology has already garnered strategic investment interest from Astellas and a collaboration agreement with Roche. Other advancements of the company's technology would be deploying a dual antigen targeting approach with P-CD19CD20-ALLO1, targeting solid tumors with P-MUC1C-ALLO1, increased dosing of lymphodepletion, piggyBac cargo, and higher CAR-T dosing. Read the full article on Seeking Alpha분석 기사 • Jan 24
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Dec 18
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Despite an already strong run, Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) shares have been powering on, with a gain of...분석 기사 • Aug 13
New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Shareholders in Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) may be thrilled to learn that the analysts have just...분석 기사 • Apr 17
Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
To the annoyance of some shareholders, Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) shares are down a considerable 44% in...Seeking Alpha • Sep 04
Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Summary Poseida announced a collaboration agreement on Aug.3 focused on allogeneic CAR-T Program in hematologic cancers with Roche, potentially worth $6 billion; $110 million upfront, $110 million in near-term milestones; other collaboration benefits. This is Poseida's second major collaboration deal following Takeda collaboration agreement focused on gene therapy products announced in October 2021. Poseida advancing internally developed genetic engineering platform technologies: non-viral piggyBac DNA delivery system, Cas-CLOVER gene editing systems, and nanoparticle and AAV-based gene delivery technologies, to develop cell and gene therapeutics. While advancing autologous CAR-T product P-PSMA-101 in Ph1 mCRPC & salivary gland carcinoma trial, Poseida is focused on advancing allogeneic CAR-T products including P-BCMA-ALL01 in Ph1 trial in refractory multiple myeloma (now licensed to Roche), and P-MUCIC-ALL01 in a Ph1 trial in a wide range of solid tumours. 2 Ph 1 preliminary readouts in H2 2022. Following the Roche deal, Poseida announced secondary financing at $3.50 per share, raising $80.5 MM gross. Poseida's $300M market cap is equal to Poseida's cash (or equivalent). Poseida appears undervalued. Poseida Therapeutics logo (Poseida Thereapeutics website) San Diego-based Poseida Therapeutics, Inc. (PSTX) is a clinical-stage biopharmaceutical company that has developed a suite of proprietary genetic engineering platform technologies to create differentiated cell and gene therapeutics with the potential to cure cancers, rare diseases and beyond with a single treatment with minimal side effects. Poseida's market cap of approximately $300 million is equal to its current estimated $300 million in cash (or equivalents), which includes a recent $110 million received from Roche described in more detail below. For the reasons discussed in this article, the author believes Poseida is currently undervalued. Poseida's Three Platforms of Genetic Engineering (Poseida's August 2022 Presentation) Poseida's three central internally developed technology platforms include: Super piggyBac DNA delivery system (Poseida June 2022 corporate presentation) a non-viral Super piggyBac DNA delivery system for gene insertion, which provides versatility in DNA delivery; a non-viral Cas-CLOVER site-specific gene editing system; and a nanoparticle and AAV-based gene delivery system. Poseida believes its technologies provide a differentiated and disruptive innovation in CAR-T cell and gene therapies with the potential to create single-treatment cures. While Poseida works with third parties contract manufacturers to produce its product candidates, it recently completed building its pilot GMP manufacturing facility in San Diego, California, adjacent to its headquarters to develop and manufacture preclinical materials and clinical supplies for its allogeneic CAR-T Phase 1 and 2 clinical trials. (Source: Form 10-Q filed with the SEC on August 11, 2022). Roche Strategic Global Collaboration Agreement: On August 3, 2022, Poseida announced a strategic global collaboration agreement with F. Hoffmann La Roche Ltd. and Hoffmann-La Roche Inc. (collectively "Roche") (RHHBY) (the "Roche Agreement") potentially worth up to $6 billion. The deal includes the payment of $110 million upfront, with an additional $110 million in near-term milestone payments based on what Poseida's CEO describes as readily achievable targets that can likely be met. The Roche Agreement became effective upon the expiration or termination of the applicable waiting period (generally 30 days) under the Hart-Scott-Rodino Antitrust Improvements Act of 1975. Accordingly, it is anticipated the Roche Agreement will close and be effective by the publication date of this article or shortly thereafter. The Company held an investor webcast on August 3 to discuss the Roche deal. The webcast is available on the Company's website here. $80,500,000 Follow-up Financing: On August 4, Poseida announced a $70,000,000 financing (20 million shares at $3.50) subject to an additional 30-day 15% broker/underwriter options, all of which were exercised, and which raised gross proceeds of $80,500,000 (approximately $75.3 Million net after fees). Poseida's Prospectus Supplement filed on August 4, 2022, with the SEC will be referred to below from time to time as well as the Company's Form 10-Q filed with the SEC on August 11, 2022. I also had a 30-minute Zoom call with Poseida's CEO Mark Gergen on August 9 prior to writing this article. Investment Summary: Poseida's differentiated proprietary genetic engineering technologies are being used to develop and advance next-generation cell and gene therapeutics. Poseida's newly announced global collaboration deal with Roche (relating to its existing and additional next-generation allogeneic CAR-T cell therapies in the treatment of hematologic malignancies, potentially worth $6 billion and up to $220 million upfront or near term), follows the announcement in October 2021 of a major Takeda (TAK) collaboration deal worth up to $3.6 billion, relating to Poseida's gene therapy technology. The Roche and Takeda agreements help validate the science, value and potential of Poseida's technology platforms and substantially defray Poseida's future clinical trial and development costs. Poseida's market cap of approximately $300 million is equal to the estimated $300 Million value of its cash (or equivalents) which Poseida is anticipated to have in early September. The author believes that the current market cap undervalues Poseida's cell and gene platform technologies, multiple cell and gene therapy clinical programs, pre-clinical pipeline, intellectual property and cash. There appears to be a disconnect in how the scientific and industry community (as validated by the recent Roche Agreement and the Takeda Agreement) views the value of Poseida versus how the market is valuing the Company. Poseida's upcoming catalysts include two near-term H2 readouts in two Phase 1 clinical trials as well as the likelihood of receiving an additional $110 million in near-term milestone payments from Roche (which Poseida indicates are milestones that are highly likely to be met within a year, if not sooner). While Poseida has great promise, it remains an early-stage, high-risk company, suitable for risk-tolerant investors. Poseida Therapeutics, Inc.: Corporate Summary PSTX data by YCharts 1 Year Share Price Range: $1.82 to $8.65 Share Price: Close on September 1, 2022: $3.52 Market Cap, close on September 1, 2022: Approximately $300 Million 85,728,726 common shares outstanding following recent financing: $80,500,000 gross proceeds, or approx. $75.3 million net after fees. There are 85,728,726 common shares outstanding following the recent $80,500,000 financing. (Source: Prospectus Supplement) The 85,728,726 shares do not include the 12,578,225 outstanding options (weighted average exercise price of $8.06), 2,275,267 restricted stock units, 121,122 warrants ($4.96 average exercise price), 2,614,787 shares that can be issued under the 2020 Equity Incentive Plan, and 1,621,649 shares reserved for future issuance under Employee Stock Purchase Plan. (Source: Prospectus Supplement) Unaudited cash and equivalents as of June 30, 2022: approx. $142.6 million (Source: Prospectus Supplement) Cash (estimated by the writer) as of early September 2022: including the $110 million upfront received from Roche and the net $75.3 million received from this month's financing, I have estimated Poseida's current cash position at approximately $300 million (my estimate). Cash Burn: According to its Form 10-Q, filed with the SEC on August 11, 2022, Poseida utilized net cash of $91.1 million during the 6 months ending June 30, 2022. Under the terms of the Roche Agreement, Roche will assume certain clinical trial costs in the future but I am assuming that the cash burn rate will continue at its present rate for the next few years. The Company has provided guidance that conservatively, it currently has sufficient liquidity to carry out its current plans into mid-2024 without taking into account most of the second anticipated $110 million in milestone payments that can be earned in the near term under the Roche Agreement, or including any other milestone payments under either the Roche or Takeda agreements. Term Debt: According to the Company Form-10Q, Poseida entered into a Loan and Security Agreement with Oxford Finance LLC, as amended in February 2022 under which the Company borrowed $60 million in term loans. Interest-only payments are payable through to April 1, 2025, followed by 23 equal monthly payments of principal and applicable interest, and other terms. The loan may be repaid on terms prior to February 22, 2024, after which it may be repaid without any prepayment penalty. Poseida's Cell Therapy Pipeline: In addition to its gene therapy pipeline (discussed later), Poseida's Cell Therapy pipeline includes an autologous "auto" as well as allogeneic "allo" chimeric antigen receptor T cell therapies, commonly known as "CAR-T" therapies, in the treatment of various cancers, including solid tumors, multiple myeloma, B-Cell and Heme Malignancies. For those unfamiliar with the terms, "autologous" CAR-T are derived from the cells of the patient being treated (being a custom and generally very expensive process and potentially deriving cells from a sick and often elderly individual), while an "allogeneic" CAR-T is derived from a third-party donor's cells which can be replicated making it a cheaper "off the shelf" product, and generally derived from a younger healthy donor. Poseida is focused on advancing its allogeneic CAR-T therapies where it believes the future of CAR-Ts lie, although it began clinical development with an autologous CAR-T cell program, P-PSMA-101, discussed in more detail below, which Poseida believes has provided substantial learnings. Poseida's Differentiated Technology: As Poseida's CEO Mark Gergen discussed during the August 3 webcast, one of Poseida's differentiators is its focus on Tscm cells, otherwise known as stem cell memory T cells, which Poseida believes are "the ideal cell type for allogeneic cell therapies.” Poseida believes it has shown that its proprietary non-viral Cas-CLOVER gene editing technology is a superior method of producing CAR-T cell therapies which use T cells that are genetically modified. In a peer-reviewed paper published June 29, 2022 in the Journal of Molecular Therapy Nucleic Acids (authored by members of the Poseida team, including founder Dr. Eric Ostertag, MD, Ph.D.), Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells, Poseida's Cas-CLOVER gene editing has been shown to preserve a higher percentage of Tscm cells, which have a self-renewing capacity, low off-target activity, and a more effective anti-tumour response. As set out in the paper's abstract, The use of T cells from healthy donors for allogeneic chimeric antigen receptor T (CAR-T) cell cancer therapy is attractive because healthy donor T cells can produce versatile off-the-shelf CAR-T treatments. To maximize safety and durability of allogeneic products, the endogenous T cell receptor and major histocompatibility complex class I molecules are often removed via knockout of T cell receptor beta constant (TRBC) (or T cell receptor alpha constant [TRAC]) and B2M, respectively. However, gene editing tools (e.g., CRISPR-Cas9) can display poor fidelity, which may result in dangerous off-target mutations. Additionally, many gene editing technologies require T cell activation, resulting in a low percentage of desirable stem cell memory T cells (TSCM). We characterize an RNA-guided endonuclease, called Cas-CLOVER, consisting of the Clo051 nuclease domain fused with catalytically dead Cas9. In primary T cells from multiple donors, we find that Cas-CLOVER is a high-fidelity site-specific nuclease, with low off-target activity. Notably, Cas-CLOVER yields efficient multiplexed gene editing in resting T cells. In conjunction with the piggyBac transposon for delivery of a CAR transgene against the B cell maturation antigen (BCMA), we produce allogeneic CAR-T cells composed of high percentages of TSCM cells and possessing potent in vivo anti-tumor cytotoxicity." Poseida's Three Ongoing Phase 1 CAR-T Clinical Trials As shown in the Cell Therapy Pipeline slide below (also described in Poseida's Prospectus Supplement), Poseida currently has three ongoing Phase 1 CAR-T clinical trials: P-PSMA-101 Interim Ph 1 Clinical Results (Poseida June 2022 Presentation) P-PSMA-101, an autologous CAR-T targeting prostate-specific membrane antigen "PSMA" developed to treat metastatic castrate-resistant prostate cancer "mCRPC" and salivary gland carcinoma. Encouraging preliminary Phase 1 results in mCRPC were presented by Dr. Susan Slovin of Memorial Sloan Kettering Cancer Center on February 17, 2022 at ASCO-GU. A short video of Dr. Slovin's ASCO-GU presentation of those results and describing P-PSMA-101 is available here. A slide presentation above summarized the interim Phase 1 clinical data presented at ASCO-GU. Poseida indicates that further clinical results from this P-PSMA-101 Phase 1 trial will likely be presented in 2023. (Note: A second-generation allogeneic CAR-T program, P-PSMA-ALL01, targeting PSMA is currently in pre-clinical development). P-BCMA-ALL01, a fully allogeneic CAR-T targeting BMCA developed to target relapsed/refractory multiple myeloma. Initial clinical results are expected to be released in H2 2022, subject to coordination with Roche. P-BCMA-ALL01 will be exclusively licensed to Roche under the newly announced Roche agreement. Under the Roche agreement, Roche will be responsible for the majority of development costs for P-BCMA-ALL01 and will assume all development costs following the completion of the Phase 1 trial. P-MUC1C-ALL01, a fully allogeneic CAR-T to treat solid cancer tumours, remains fully owned by Poseida. Initial Phase 1 results are expected to be released in H2 2022 and if successful, will help validate Poseida's thesis of developing CAR-Ts with a larger proportion of Tscm T-cells to safely and effectively treat solid tumours. Poseida's Global Collaboration Agreement with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Cancers Announced August 3, 2022 Poseida announced a strategic global collaboration and licensing agreement with Roche (RHHBY) to advance a number of Poseida's existing and additional next-generation allogeneic CAR-T cell therapies in the treatment of hematologic malignancies. Poseida retained full rights to its allogeneic CAR-T cell programs in solid tumours. Poseida's Global Partnership with Roche (Poseida August 2022 corporate presentation) Under the Roche Agreement, Poseida will receive $110 million upfront and up to an additional $110 million in near-term milestones, which Poseida believes is highly achievable. In my recent conversation with Mark Gergen, he confirmed that by "near-term" he meant that the $110 million in milestones would highly likely be achieved within approximately 12 months. In addition, Poseida is eligible for additional net milestones and other payments from Roche potentially worth up to $6 billion in value, as well as tiered royalties into the low double-digits on net sales royalties. In return, Roche gets access to a number of "off-the-shelf" allogeneic CAR-Ts for hematologic malignancies, including P-BCMA-ALLO1 for multiple myeloma, (currently in a Phase I study), and P-CD19CD20-ALLO1, described as an allogeneic "dual CAR-T" for B-cell malignancies, for which an IND is anticipated to be filed in 2023. Poseida and Roche will also work on additional targets. Economic Summary of Roche Agreement (Poseida August 3, 2022 presentation) Strategic Rationale for Roche Agreement (Poseida August 3, 2022 presentation) Collaboration Scope of Roche Agreement (Poseida August 3, 2022 presentation) October 2021: Poseida - Takeda Collaboration Agreement in Gene Therapy The Roche deal follows a major research collaboration and licensing deal in In-Vivo gene therapy that Poseida entered into with Takeda Pharmaceutical Company Ltd. (TAK), announced on October 12, 2021.Seeking Alpha • Aug 11
Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Poseida Therapeutics press release (NASDAQ:PSTX): Q2 GAAP EPS of -$0.69 beats by $0.08. Revenue of $2.7M beats by $1.77M.Seeking Alpha • Aug 03
Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
The shares of clinical-stage biotech Poseida Therapeutics (NASDAQ:PSTX) spiked ~56% in the pre-market Wednesday after the company announced a partnership with Roche (OTCQX:RHHBY) (OTCQX:RHHBF) to jointly develop allogeneic CAR-T therapies in a deal valued at up to $6B. Per the terms, the Swiss pharma giant will receive either exclusive rights or options from Poseida (PSTX) to develop and sell multiple "off-the-shelf" CAR-T assets globally against the targets in multiple myeloma, B-cell lymphomas, and other hematologic malignancies. In return, Poseida (PSTX) will receive $110M of upfront payment in addition to $110M in near-term milestones and other payments within the next several years. Notably, the company is entitled to receive up to $6B worth of milestones and other payments based on research, development, launch, and net sales. The completion of the agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act). The deal with Roche (OTCQX:RHHBY) comes months after Poseida (PSTX) elevated its former President and Chief Business Officer, Mark Gergen, as its new Chief Executive.분석 기사 • May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
It's been a sad week for Poseida Therapeutics, Inc. ( NASDAQ:PSTX ), who've watched their investment drop 12% to...Seeking Alpha • Oct 30
Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Poseida has built a non-viral genome engineering platform to develop safer cell therapies in oncology. This platform could enable outpatient use and expand the number of patients who can receive a cell therapy as well as bringing in substantial partnerships. Poseida's lead drug candidate, P-BCMA-101, has shown outstanding safety in a Phase 1 trial but needs more data on its efficacy. As a result, we recommend monitoring the stock until more data is released for the expanded Phase 1 trial for Poseida's lead asset.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$113m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$3m | US$381k | -US$123m |
보상 대 시장: Kristin의 총 보수(USD2.58M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.70M) 수준입니다.
보상과 수익: Kristin의 보상을 회사 실적과 비교하기에 데이터가 부족합니다.
CEO
Kristin Yarema (52 yo)
1yr
재임 기간
US$2,581,106
보수
Dr. Kristin Yarema, Ph D., is President & CEO of Poseida Therapeutics, Inc. since January 01, 2024, and serves as its Director since January 2024. Dr. Yarema was the Chief Commercial Officer and Senior Vic...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chairman of the Board | 7yrs | US$3.82m | 0.19% $ 1.8m | |
| President | 1yr | US$2.58m | 데이터 없음 | |
| Chief Financial Officer | 4.5yrs | 데이터 없음 | 0.073% $ 678.4k | |
| Chief Operations Officer | 3yrs | 데이터 없음 | 데이터 없음 | |
| Chief People & Administration Officer | 6yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP of Investor Relations & Corporate Communications | less than a year | 데이터 없음 | 데이터 없음 | |
| General Counsel | 4.5yrs | US$978.34k | 0.040% $ 375.9k | |
| Chief Scientific Officer of Cell Therapy | 4.9yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Regulatory Affairs | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Patent Counsel | 3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Business Development | 3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | less than a year | 데이터 없음 | 데이터 없음 |
3.0yrs
평균 재임 기간
57yo
평균 나이
경험이 풍부한 관리: PSTX의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chairman of the Board | 7yrs | US$3.82m | 0.19% $ 1.8m | |
| President | 1yr | US$2.58m | 데이터 없음 | |
| Lead Independent Director | 6.5yrs | US$175.11k | 0.040% $ 375.7k | |
| Chairman of Cell Therapy Scientific Advisory Board | 3.8yrs | 데이터 없음 | 데이터 없음 | |
| Chairman of Gene Therapy Scientific Advisory Board | 2.5yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 6yrs | US$149.11k | 0.050% $ 471.3k | |
| Independent Director | 3.5yrs | US$155.28k | 0.040% $ 375.7k | |
| Independent Director | 2.7yrs | US$150.28k | 0.047% $ 438.3k | |
| Independent Director | 4.1yrs | US$140.11k | 0.040% $ 375.7k | |
| Member of Scientific Advisory Board | 3.7yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.7yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.7yrs | 데이터 없음 | 데이터 없음 |
3.7yrs
평균 재임 기간
66yo
평균 나이
경험이 풍부한 이사회: PSTX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 3.7 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2025/01/07 09:10 |
| 종가 | 2025/01/07 00:00 |
| 수익 | 2024/09/30 |
| 연간 수익 | 2023/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Poseida Therapeutics, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Alec Stranahan | BofA Global Research |
| null null | H.C. Wainwright & Co. |
| Yu He | H.C. Wainwright & Co. |